Effects of sacubitril/valsartan according to polypharmacy status in PARAGON ‐HF

ConclusionsPolypharmacy is very common in patients with HFpEF, and those with polypharmacy have worse clinical status and a higher rate of non-fatal and fatal outcomes. The benefit of sacubitril/valsartan was not diminished in patients taking a larger number of medications at baseline.

Source: European Journal of Heart Failure - April 8, 2024 Category: Cardiology Authors: Shingo Matsumoto, Mingming Yang, Li Shen, Alasdair Henderson, Brian L. Claggett, Akshay S. Desai, Martin Lefkowitz, Jean L. Rouleau, Orly Vardeny, Michael R. Zile, Pardeep S. Jhund, Muthiah Vaduganathan, Scott D. Solomon, John J.V. McMurray Tags: Research Article Source Type: research